Meningococcemia (Meningococcal Infections) - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 42 pages report, published by Global Markets Direct

Keywords : Meningococcemia (Meningococcal Infections) Therapeutic Products under Development, Key Players in Meningococcemia (Meningococcal Infections) Therapeutics, Meningococcemia (Meningococcal Infections) Pipeline Overview, Meningococcemia (Meningococcal Infections) Pipeline, Meningococcemia (Meningococcal Infections) Pipeline Assessment

Report ThumbnailSeptember-2013
Meningococcemia (Meningococcal Infections) - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Meningococcemia (Meningococcal Infections) - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Meningococcemia (Meningococcal Infections), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Meningococcemia (Meningococcal Infections). Meningococcemia (Meningococcal Infections) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Meningococcemia (Meningococcal Infections).
- A review of the Meningococcemia (Meningococcal Infections) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Meningococcemia (Meningococcal Infections) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Meningococcemia (Meningococcal Infections).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Meningococcemia (Meningococcal Infections) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Meningococcemia (Meningococcal Infections), H2 2013 7
  • Products under Development for Meningococcemia (Meningococcal Infections) - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Products under Investigation by Universities/Institutes, H2 2013 10
  • Late Stage Products, H2 2013 11
  • Mid Clinical Stage Products, H2 2013 12
  • Discovery and Pre-Clinical Stage Products, H2 2013 13
  • Assessment by Monotherapy Products, H2 2013 21
  • Assessment by Route of Administration, H2 2013 22
  • Assessment by Stage and Route of Administration, H2 2013 23
  • Assessment by Molecule Type, H2 2013 24
  • Assessment by Stage and Molecule Type, H2 2013 25
  • List of Tables
  • Number of Products Under Development for Meningococcemia (Meningococcal Infections), H2 2013 7
  • Products under Development for Meningococcemia (Meningococcal Infections) - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Number of Products under Investigation by Universities/Institutes, H2 2013 10
  • Comparative Analysis by Late Stage Development, H2 2013 11
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 13
  • Products under Development by Companies, H2 2013 14
  • Products under Investigation by Universities/Institutes, H2 2013 15
  • GlaxoSmithKline plc, H2 2013 16
  • Biological E. Limited, H2 2013 17
  • Panacea Biotec Limited, H2 2013 18
  • Wellstat Vaccines, LLC, H2 2013 19
  • Beijing Minhai Biotechnology Co., Ltd, H2 2013 20
  • Assessment by Monotherapy Products, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 25
  • Meningococcemia (Meningococcal Infections) Therapeutics - Dormant Products 36
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Meningococcemia (Meningococcal Infections) Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Meningococcemia (Meningococcal Infections) 7
  • Meningococcemia (Meningococcal Infections) Therapeutics under Development by Companies 9
  • Meningococcemia (Meningococcal Infections) Therapeutics under Investigation by Universities/Institutes 10
  • Late Stage Products 11
  • Comparative Analysis 11
  • Mid Clinical Stage Products 12
  • Comparative Analysis 12
  • Discovery and Pre-Clinical Stage Products 13
  • Comparative Analysis 13
  • Meningococcemia (Meningococcal Infections) Therapeutics - Products under Development by Companies 14
  • Meningococcemia (Meningococcal Infections) Therapeutics - Products under Investigation by Universities/Institutes 15
  • Companies Involved in Meningococcemia (Meningococcal Infections) Therapeutics Development 16
  • GlaxoSmithKline plc 16
  • Biological E. Limited 17
  • Panacea Biotec Limited 18
  • Wellstat Vaccines, LLC 19
  • Beijing Minhai Biotechnology Co., Ltd 20
  • Meningococcemia (Meningococcal Infections) - Therapeutics Assessment 21
  • Assessment by Monotherapy Products 21
  • Assessment by Route of Administration 22
  • Assessment by Molecule Type 24
  • Drug Profiles 26
  • Meninge ACYW Conjugate - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • GSK-134612 - Drug Profile 27
  • Product Description 27
  • Mechanism of Action 27
  • R&D Progress 27
  • Meningitis Vaccine - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • Meningococcus B Vaccine - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • Meningococcus CY Polysaccharide Conjugate Vaccine - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • Meningococcal B Vaccine - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • Meningococcal ACW135 Vaccine (Plain) - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • Meningococcal ACYW135 Vaccine (Plain) - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • Meningococcal ACYW135X Vaccine (Plain) - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • Meningococcemia (Meningococcal Infections) Therapeutics - Dormant Products 36
  • Meningococcemia (Meningococcal Infections) - Product Development Milestones 37
  • Featured News & Press Releases 37
  • Jan 14, 2013: Novartis's Bexsero Shows Potential To Help Provide Broad Protection To Infants Against MenB In Phase III Clinical Trial 37
  • Dec 03, 2012: Sanofi Pasteur Canada Receives Health Canada Approval Of Menactra Meningococcal Conjugate Vaccine Indication For Infants 38
  • Nov 08, 2012: Sanofi Pasteur Announces Publication Of Pivotal Safety And Immunogenicity Data Of Menactra Vaccine For Infants And Toddlers 39
  • Apr 22, 2011: Sanofi Pasteur Announces FDA Approval Of Menactra Meningococcal Conjugate Vaccine Indication for Infants 39
  • Dec 23, 2010: Novartis Submits Meningococcal B Vaccine For Regulatory Review In Europe 40
  • Appendix 41
  • Methodology 41
  • Coverage 41
  • Secondary Research 41
  • Primary Research 41
  • Expert Panel Validation 41
  • Contact Us 42
  • Disclaimer 42

Please select a license type

Share

Related Products

Global Markets DirectMeningococcemia (Meningococcal Infections) - Pipeline Review, H2 2013Product ThumbnailMeningococcemia (Meningococcal Infections) - Pipeline Review, H2 2013, Industry ReportProduct #: 113327
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved